Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04879420 · ClinicalTrials.gov registry record
Replication of the VERO Osteoporosis Trial in Healthcare Claims Data
A clinical trial, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- 12,757
- Enrollment target
NCT04879420: Completed study, sponsored by Brigham and Women's Hospital.
NCT04879420 is a clinical trial that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 12,757 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04879420 has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- 12,757 participants
- Enrollment target
Study Summary
Investigators are building an empirical evidence base for real world data through large-scale replication of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.
Primary Outcome
Claims-based algorithm based on diagnosis codes for vertebral fractures. Please refer to study protocol in Documents Section for full details
Interventions
- DRUG Risedronate
- DRUG Teriparatide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12,757 participants |
| Start Date | 2020-10-29 |
| Est. Completion | 2021-06-11 |
What the finished NCT04879420 record still lists
NCT04879420 is an observational study that tracks outcomes without assigning an intervention. Its 12,757 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 2 interventions - of which Risedronate is the first listed.
NCT04879420 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04879420 about?
NCT04879420 is a clinical study titled "Replication of the VERO Osteoporosis Trial in Healthcare Claims Data". Investigators are building an empirical evidence base for real world data through large-scale replication of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such...
What is the current status of trial NCT04879420?
This trial is currently completed. The enrollment target is 12,757 participants. The study started on 2020-10-29. Estimated completion is 2021-06-11.
What interventions are being tested in trial NCT04879420?
The interventions under investigation include: Risedronate (DRUG), Teriparatide (DRUG).
Who is sponsoring clinical trial NCT04879420?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07037433 · 12,800 participants · Phase 3
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
- NCT03586895 · 12,838 participants · NA
e-Connect: A Service System Intervention for Justice Youth at Risk for Suicide
- NCT07028398 · 12,990 participants · NA
CMSL Ambulatory Sensitive Condition Nudge Study 2
- NCT05991453 · 13,000 participants · NA
Trajectories of Recovery After Intravenous Propofol Versus Inhaled VolatilE Anesthesia Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI